about
Synaptic Plasticity, a Prominent Contributor to the Anxiety in Fragile X SyndromeAutism spectrum disorders and neuropathology of the cerebellumHeterogeneity within Autism Spectrum Disorders: What have We Learned from Neuroimaging Studies?Psychiatric symptoms in boys with fragile X syndrome: a comparison with nonsyndromic autism spectrum disorder.Cognitive Aspects of Fragile X syndrome.The role of genetics in the establishment and maintenance of the epigenome.Changes in sensitivity of reward and motor behavior to dopaminergic, glutamatergic, and cholinergic drugs in a mouse model of fragile X syndromeIn vivo neuronal function of the fragile X mental retardation protein is regulated by phosphorylationCharacterization, treatment patterns, and patient-related outcomes of patients with Fragile X syndrome in Germany: final results of the observational EXPLAIN-FXS study.New insights of altered lipid profile in Fragile X Syndrome.Do the data really support ordering fragile X testing as a first-tier test without clinical features?Characterising repetitive behaviours in young boys with fragile X syndrome.Improving preimplantation genetic diagnosis for Fragile X syndrome: two new powerful single-round multiplex indirect and direct tests.Is metabotropic glutamate receptor 5 upregulated in prefrontal cortex in fragile X syndrome?Live birth following serial vitrification of embryos and PGD for fragile X syndrome in a patient with the premutation and decreased ovarian reserve.BRCA1/2 mutations and FMR1 alleles are randomly distributed: a case control studyHuman pluripotent stem cell models of autism spectrum disorder: emerging frontiers, opportunities, and challenges towards neuronal networks in a dishMicrodeletions including FMR1 in three female patients with intellectual disability - further delineation of the phenotype and expression studies.Emerging Roles for Long Non-Coding RNAs in Cancer and Neurological Disorders.Recent advances in clinical neurogenetics.Neural and behavioral epigenetics; what it is, and what is hype.Hippocampal metabotropic glutamate receptor long-term depression in health and disease: focus on mitogen-activated protein kinase pathways.Single-locus enrichment without amplification for sequencing and direct detection of epigenetic modifications.Human pluripotent stem cells in modeling human disorders: the case of fragile X syndrome.Detailed assessment of incontinence in boys with fragile-X-syndrome in a home setting.Symptoms of Autism in Males with Fragile X Syndrome: A Comparison to Nonsyndromic ASD Using Current ADI-R Scores.Homicide, fragile X syndrome, and mental retardation.Dendritic channelopathies contribute to neocortical and sensory hyperexcitability in Fmr1(-/y) mice.Fragile X testing as a second-tier test.Platelets as a surrogate disease model of neurodevelopmental disorders: Insights from Fragile X Syndrome.Dysfunctional Autism Risk Genes Cause Circuit-Specific Connectivity Deficits With Distinct Developmental Trajectories.Sensory Difficulties in Children With an FMR1 Premutation
P2860
Q26745117-1A2A6FBE-7009-4D13-8F7C-AF202099D0A6Q26853603-600FD478-FFD7-472D-B437-48709D645478Q30689991-B88CD108-9C2D-4B9F-9783-61D9BE0ACA62Q33565886-698488C5-3413-4A04-A095-5C2545463839Q34626140-8D2F0939-88A2-4344-85FF-0CCA53C12620Q34649133-AFB6619E-BE0C-4ABF-9030-6AEA5D340586Q35035766-D5493D3C-FE0A-4360-8DE0-4062042296A9Q35688627-3E128763-B0CA-48D4-9E48-3F2A8F0A3377Q36128713-BD8DDAA2-E79F-4361-A7AC-F19D1F699F1BQ36320196-B2DACCD9-CC09-4711-8E02-7AC6D7FB9179Q36379814-76746036-A2EB-49FF-B6AE-0DBE584A5800Q36470234-A5AE196F-F3D9-4254-9A12-9B61F5F57FBCQ36475081-BF19652F-B8E5-4A82-8C72-D6A3DC0076BCQ36921816-8932AEE2-A42F-45F2-97B4-E913C9C59699Q37429884-F82B9CBA-2BCA-459D-8847-9F20F0F4A94BQ37493145-AD0FDFDC-338F-4C2C-AEB5-F677D443618CQ37598427-D90B56B7-EBBB-4E6D-967B-54ED60EA219BQ37687732-25211689-E9EE-456D-B037-DCBAAFC7E80CQ37989144-71C8DCB8-2631-4FD9-944D-28E5CD4F7768Q38060657-CD0BDC1F-A140-43AF-9EDB-9790B7FCD0D0Q38262868-ADF98ED6-FCDA-450D-99F9-63D2A38404B6Q38753843-CB270AD9-81B2-492F-8866-161CBA70601DQ38798182-943E2CE7-8519-43A0-8B09-71DD968185C7Q39024323-EC589B4B-22BF-4647-B19B-93C6F99D188EQ40604881-52263B9B-516C-4982-8C48-96B61EF9019CQ42734292-0E662F53-A6AD-4824-A999-C030B07D0DBDQ44169483-82BC1C91-38CD-40B5-8B4C-764D8E83C9A5Q48460762-9B56DEEA-EA91-4A78-8AE8-9BCFD714A60BQ50073161-1FB54205-47CB-4A2E-A4A1-7DA69FA39589Q50307674-C6D4B1D0-66B0-42FD-A374-9C29EE1DFCAFQ55257259-F831FBE1-7479-4108-82C3-452B2FF4780FQ58697860-8EAE3A64-A1B2-407C-9917-5634DA079E71
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Fragile X-associated disorders: a clinical overview.
@en
Fragile X-associated disorders: a clinical overview.
@nl
type
label
Fragile X-associated disorders: a clinical overview.
@en
Fragile X-associated disorders: a clinical overview.
@nl
prefLabel
Fragile X-associated disorders: a clinical overview.
@en
Fragile X-associated disorders: a clinical overview.
@nl
P2860
P1433
P1476
Fragile X-associated disorders: a clinical overview
@en
P2093
Anne Gallagher
P2860
P2888
P304
P356
10.1007/S00415-011-6161-3
P577
2011-07-12T00:00:00Z